Axalta today said it is launching a review of strategic alternatives, including a potential sale of the company. Axalta shares jumped 13.6% after the news on 19 June, closing at $29.33.
The company has formed a strategic review committee chaired by independent presiding director Mark Garrett. The committee also includes Axalta CEO Robert Bryant and independent director Samuel Smolik.
“Axalta continues to execute on its long-term strategy, delivering significant cost savings to bolster our industry-leading margins, redeploying free cash flow to drive accretive organic and inorganic growth initiatives, and returning more than $380 million to shareholders over the last two years,” Bryant says.
Axalta’s largest shareholder is Berkshire Hathaway, with a 10.3% stake. Barclays and Evercore are acting as financial advisors to Axalta on the review, and Morrison & Foerster is acting as legal advisor.
The company is facing headwinds from soft automotive production, although pressure on margins seems likely to abate given a recent pullback in energy prices, says Laurence Alexander, an analyst with Jefferies (New York). “Axalta has discussed a sale of the company in the past, and our model pegs the company value at $38/share,” Alexander adds. “Over the past three years, bolt-on M&A and share repurchases have been the first use of cash.”
The timing and outcome are uncertain, and Axalta says it will not comment on the review until it is complete.
By Vincent Valk
Source: Chemical Week
Corteva (Indianapolis, Indiana) says it has signed a definitive agreement to acquire Stoller Group (Houston, Texas), a producer of biostimulants and plant nutrition products, for $1.2 billion. Stoller is one of the largest independent biologicals companies globally, with operations in more than 60 countries and more than $400 million in annual sales.
OMV has announced its new corporate structure today, designed to fully enable the delivery of Strategy 2030. The new organization will be built on five distinct areas. In addition to the CEO and CFO areas, three business segments will be established: Chemicals & Materials, Fuels & Feedstock, and Energy.
The European petchem sector is readying for some tough quarters. It’s a different picture in the US. So is this the best time ever to find a new role in the chemical industry? If you are in Europe, you would expect me to say probably not. But actually, it depends. So let me give you four answers to this question.